Back to top
more

Bruker (BRKR)

(Delayed Data from NSDQ)

$63.54 USD

63.54
1,595,375

-2.34 (-3.55%)

Updated Aug 5, 2024 04:00 PM ET

After-Market: $63.56 +0.02 (0.03%) 7:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 251)

Industry: Instruments - Scientific

Better trading starts here.

Zacks News

Computer Programs and Systems to Offer Microsoft HealthVault

Computer Programs and Systems' (CPSI ) move indicates its efforts to strengthen foothold in the healthcare information technology (HCIT) space.

Zimmer Biomet Grows Internationally Despite Pricing Pressure

Zimmer Biomet (ZBH) witnesses strength in the EMEA and APAC regions as well as in the Spine & CMF business.

Align (ALGN) Introduces Intraoral Scanner, Aids iTero Uptake

The latest development in Align Technology's (ALGN) iTero arm is expected to be a perfect strategic fit for the company as it will help it further grow its patient base for intraoral scanner.

Insulet (PODD) Hits 52-Week High on Solid Growth Prospects

Insulet (PODD) gains from steady global expansion as well as rollout of innovative products like Omnipod DASH and Omnipod Horizon automated insulin delivery system.

Here's Why You Should Add Cardiovascular Systems (CSII) Stock

Cardiovascular Systems (CSII) gains on high investors' confidence, courtesy of consistent positive results.

Boston Scientific's New Products, Acquisitions Boost Growth

Boston Scientific (BSX) is pulling out all the stops to strengthen its core businesses as well as invest in new technologies and the overseas markets.

Boston Scientific (BSX) Announces Vertiflex Acquisition

The acquisition is in sync with Boston Scientific's (BSX) strategy of expanding pain management portfolio.

Top Ranked Momentum Stocks to Buy for June 12th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 12th

Here's Why Bruker (BRKR) is a Great Momentum Stock to Buy

Does Bruker (BRKR) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why You Should Hold on to QIAGEN (QGEN) Stock Now

QIAGEN (QGEN) is enjoying investors' high confidence, courtesy of the QIAstat-Dx system.

Thermo Fisher Abandons Gatan Deal in Want of European Nod

Thermo Fisher (TMO) and Roper will carry on with their current long-term supply agreement.

Medtronic Delivers Favorable Outcome on Guardian Connect

Medtronic's (MDT) data indicates that Guardian Connect will enable patients to better understand glucose trends and increase Time in Range.

Chemed's VITAS Business Strong, Weak Acuity Mix Shifts a Woe

Chemed's (CHE) VITAS registers an expanded average daily census.

Integra LifeSciences' Organic Growth Strong on New Products

Banking on product unveilings and a better sales force performance, Integra LifeSciences (IART) pins hopes on accelerated organic growth in the second half of 2019.

Tandem Releases Positive Results Of t:slim X2 Pump Studies

The results of the studies are a major breakthrough for Tandem (TNDM) in the field of diabetes treatment.

Smith & Nephew (SNN) Buys Brainlab, Braces Robotic Ecosystem

The transaction by Smith & Nephew (SNN), besides the business purchase, comprises certain intangible assets and the orthopaedic Brainlab salesforce.

Titan Medical (TMDI) Shows Promise on Strategic Developments

Titan Medical (TMDI) is putting in a good deal of effort to strengthen its position in the multi-billion dollar computer-assisted robotic surgical technologies market.

Varian (VAR) Set to Exhibit ProBeam Proton Therapy System

Varian's (VAR) ProBeam exhibition is in sync with its strategy to expand reach within the cancer care market.

Walgreens' Weak Market Trends a Woe, Strategic Deals a Boon

Walgreens Boots (WBA) is diligently trying to redress specific areas of operational weakness and enhancing its managerial skills for a better operating performance.

QIAGEN-DiaSorin Union to Enhance QuantFERON for Lyme Disease

QIAGEN (QGEN) expects multi-site clinical validations for this new system during 2020 Lyme disease season.

Here's Why You Should Invest in Quest Diagnostics (DGX) Stock

Quest Diagnostics (DGX) is boosting investors' optimism, courtesy of consistent positive results.

LHC Group Finalizes Joint Venture Agreement With AtlantiCare

LHC Group's (LHCG) deal is in line with its current strategy of collaborating with JV partners to expand service capabilities in core markets.

Abbott (ABT) Grows on EPD Amid Rhythm Management Challenges

We are optimistic about the steady growth trend in Abbott's (ABT) EPD and Medical Devices segments on an organic basis.

Here's Why You Should Invest in Omnicell (OMCL) Stock Now

Omnicell (OMCL) is boosting investors' optimism, courtesy of consistent positive results.

Myriad Genetics' (MYGN) POLO Study Shows Positive Results

Myriad Genetics' (MYGN) collaboration with AstraZeneca garners several regulatory go-aheads for BRACAnalysis CDx test.